GetTopicDetailResponse(id=9088e904482, topicName=維昇藥業(yè), introduction=維昇藥業(yè), content=null, image=null, comments=1, allHits=1428, url=https://h5.medsci.cn/topic?id=79044, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=96101, tagList=[TagDto(tagId=96101, tagName=維昇藥業(yè))], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2257238, encodeId=1dec225e2383c, content=<a href='/topic/show?id=9088e904482' target=_blank style='color:#2F92EE;'>#維昇藥業(yè)#</a>, objectTitle=維昇藥業(yè)：引領內(nèi)分泌創(chuàng)新，重塑行業(yè)格局, objectType=article, longId=868340, objectId=1e178683401e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301015/1697393792771_4754896.jpeg, objectUrl=/article/show_article.do?id=1e178683401e, replyNumber=0, likeNumber=39, createdTime=2025-03-22, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=1e178683401e, moduleTitle=維昇藥業(yè)：引領內(nèi)分泌創(chuàng)新，重塑行業(yè)格局, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1e178683401e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=915268, encodeId=72a39152686f, content=<a href='/topic/show?id=4c14935467e' target=_blank style='color:#2F92EE;'>#軟骨發(fā)育不全#</a>是<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕見病#</a>，<a href='/topic/show?id=9088e904482' target=_blank style='color:#2F92EE;'>#維昇藥業(yè)#</a>, objectTitle=維昇藥業(yè)TransCon C-型利鈉肽II期中國臨床試驗申請獲批, objectType=article, longId=205596, objectId=d82020559619, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021110/1610261752373_5295905.jpg, objectUrl=/article/show_article.do?id=d82020559619, replyNumber=0, likeNumber=194, createdTime=2021-01-10, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d82020559619, moduleTitle=維昇藥業(yè)TransCon C-型利鈉肽II期中國臨床試驗申請獲批, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d82020559619)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
